HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Higher Safety Risk For Import Supplements Sold At 'Non-Traditional Places'

This article was originally published in The Tan Sheet

Executive Summary

FDA officials most every day find imports containing products labeled as dietary supplements but spiked with drug ingredients, or nonprescription drug products that are not compliant with US regulations. Immigrant consumers particularly are susceptible to using those products, FDA says.

You may also be interested in...



FDA Reaps More Spiked Supplements From International Mail Shipments

FDA identifies 14 products in examinations of international mail shipments found to contain approved and banned drug ingredients indicated for weight loss, erectile dysfunction and depression.

Nurish by Nature Made Capitalizes First Year With Brand, Packaging Redesign, Ashwagandha Launch

Brand’s management says its packaging redesign “was inspired by the Nature Made heritage and Nurish mission that healthy living should be joyful.” It partnered with branding consultancy Spicefire to develop brand and packaging to evoke Pharmavite’s 50 years of providing supplements.

Natural Alternatives International First To Clear NPA's, Retailers' Safety, Compliance Standards

Contract manufacturer showed compliance with Supplement Safety & Compliance Initiative standards to globally harmonize benchmarks for natul products. Retailers including Amazon and Walmart acknowledge SSCI as benchmarks companies must meet in order to sell products on their platforms.

Topics

UsernamePublicRestriction

Register

RS108829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel